Meningococcal Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Conjugate, Polysaccharide, Combination, Others), By Age Group (Infant, Children & Adult), By Region & Competition, 2021-2031F

The Global Meningococcal Vaccines Market is projected to expand from USD 4.38 Billion in 2025 to USD 6.18 Billion by 2031, reflecting a compound annual growth rate of 5.91%. These biological preparations are crucial for establishing immunity against Neisseria meningitidis bacteria, thereby preventing severe invasive conditions like meningitis and septicemia. The market's growth is primarily fuelled by the integration of these vaccines into national immunization programs and strict regulatory requirements for travelers visiting endemic areas, such as pilgrims performing Hajj and Umrah. Furthermore, revenue growth is bolstered by government-supported catch-up initiatives for adolescents and the increasing commercial adoption of Serogroup B vaccines within the private sector.

However, the market faces significant obstacles due to the substantial costs associated with vaccine development and the intricate cold-chain logistics necessary for distribution in low-income regions. These economic and logistical barriers restrict accessibility, even as rising infection rates underscore a critical public health need. For example, the Centers for Disease Control and Prevention reported 503 confirmed and probable cases of meningococcal disease in the United States in 2024, the highest annual figure since 2013. This data emphasizes the urgent demand for effective vaccines, even as supply chain complexities and pricing challenges hinder broader global market penetration.

Market Driver

A major catalyst for the market is the recent increase in invasive meningococcal disease outbreaks across Africa and Europe, which is urging governments to strengthen surveillance and implement emergency vaccination measures. This resurgence is notably affecting areas where the disease was previously thought to be managed, necessitating immediate vaccine procurement to halt transmission. According to the UK Health Security Agency in November 2025, confirmed invasive meningococcal disease cases in England increased to 378 during the 2024-25 period, up from 340 the prior year. Such epidemiological changes are prompting the expansion of national immunization schedules and catch-up campaigns, resulting in higher vaccine order volumes as authorities focus on containment.

Concurrently, the market is evolving through the distribution of advanced multivalent conjugate vaccines, which provide protection against multiple serogroups in a single dose. These innovations simplify the logistics of mass immunization, especially in high-risk areas with challenging cold-chain requirements. A significant milestone was noted by Gavi, the Vaccine Alliance, in April 2025, when Nigeria received over one million doses of the new pentavalent meningococcal conjugate vaccine (Men5CV) to fight a severe outbreak. This trend toward comprehensive formulations is improving the financial results of leading manufacturers; for instance, GSK reported in October 2025 that its meningitis vaccine sales reached £0.5 billion in the third quarter, a 5% rise driven by robust international demand.

Market Challenge

The expansion of the Global Meningococcal Vaccines Market is heavily restricted by the high costs of vaccine development coupled with the logistical difficulties of maintaining cold-chain integrity. Manufacturers face substantial expenses during research and production, leading to pricing structures that often exceed the healthcare budgets of developing nations. This economic gap is worsened by the need for strict temperature controls during transport, making distribution impractical in areas without reliable infrastructure. As a result, the market struggles to reach high-demand populations in Sub-Saharan Africa, limiting commercial viability primarily to wealthier regions with lower disease incidence.

This failure to establish affordable, routine supply chains compels the market to depend on reactive, donor-funded emergency measures rather than sustainable commercial channels. The dominance of this reactive approach is highlighted by recent operational statistics. According to Gavi, the Vaccine Alliance, by the end of 2024, the emergency stockpile for multivalent meningococcal vaccines was utilized 68 times by 16 countries, requiring the shipment of over 34.4 million doses to manage outbreaks. This underscores how financial and logistical constraints effectively limit market activity to sporadic emergency responses, hindering the shift toward a broader and more stable revenue model.

Market Trends

The commercial landscape is being transformed by the shift toward Pentavalent MenABCWY combination vaccines, which consolidate protection against five serogroups into a single regimen to address low compliance with multi-injection schedules among adolescents. This trend is especially strong in developed markets such as the United States, where pharmaceutical leaders are achieving regulatory approvals for formulations combining standard MenACWY conjugates with Serogroup B components. A key development in this transition was reported by GSK in February 2025, when the US Food and Drug Administration (FDA) approved Penmenvy, a new pentavalent vaccine for individuals aged 10 to 25. By minimizing the number of required injections, these combination products are anticipated to boost coverage rates for Serogroup B, which has historically trailed other serogroups due to complex administration protocols.

At the same time, the integration of Serogroup B vaccines into national immunization schedules represents a significant policy shift, elevating these products from private-market options to government-mandated essentials. European health authorities are increasingly prioritizing universal infant coverage to prevent the severe consequences of invasive meningococcal disease, thereby securing market volume through public procurement. This policy evolution was illustrated in January 2025, when the Ministry of Health in France made vaccination against meningococcal serogroup B mandatory for all infants, establishing a standard schedule with doses at 3, 5, and 12 months. Such regulatory changes force manufacturers to align their supply chains with national tenders, ensuring consistent demand while eliminating financial barriers that previously limited access for high-risk pediatric populations.

Key Market Players

• Sanofi S.A.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Serum Institute of India Pvt. Ltd.
• Pfizer, Inc.
• Walwax Biotechnology Co., Ltd

Report Scope

In this report, the Global Meningococcal Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Meningococcal Vaccines Market, By Type

• Conjugate
• Polysaccharide
• Combination
• Others

Meningococcal Vaccines Market, By Age Group

• Infant
• Children & Adult

Meningococcal Vaccines Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Meningococcal Vaccines Market.

Available Customizations:

Global Meningococcal Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).